KSAM

(redirected from FGFR2)
Also found in: Medical, Acronyms.

KSAM

[′kā‚sam]
(computer science)
References in periodicals archive ?
5,19) Mansukhani et al, (19) relacionan la apoptosis con el cierre prematuro de las suturas, donde los osteoblastos transfectados con genes mutados FGFR2 en Apert o Crouzon exhiben niveles muy elevados.
El objetivo para la familia 1 fue identificar a traves del analisis molecular, el caso indice y su hermano con diagnostico de labio y paladar hendido (LPH), tienen la misma mutacion, ya que se considera una posible relacion entre mutaciones en el FGFR2 y los fenotipos SA y LPH.
The crucial role of FGFR2 during testicular development has been elegantly demonstrated by Kim et al.
tropicalis, FGFR3 is expressed in the developing lens, FGFR2 is prominently expressed in corneal epithelium, and FGFR1 and FGFR4 are expressed in "cells surrounding the lens" in early tadpoles (Lea et al.
Este cambio va a provocar al igual que las mutaciones descritas en el gen del FGFR2 una mayor avidez por las proteinas que lo estimulan.
In addition, researchers found that other variants, including FGFR2, recognized to increase breast cancer risk in the general population, also served as risk modifiers for women with BRCA2 mutations.
Previously pathogenetically unclarified, the genetic cause of LADD syndrome has been identified as heterozygous mutations in the encoding of fibroblast growth factor receptors FGFR2 and FGFR3.
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.
Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation.
Presently, the product is in a phase two clinical trial for patients with chemotherapy-refractory bile duct cancer (cholangiocarcinoma) containing FGFR2 fusions.